Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -64.73% is in line with its 3-year average of -63.69%, around the middle of its 3-year range (-74.50%–-54.58%).
0.63% below its 12-month average of -64.32%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -68.58%.
NET PROFIT MARGIN
-64.73%
NET PROFIT MARGIN AVG TTM
-64.32%
NET PROFIT MARGIN AVG 3Y
-63.29%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.63%
CURRENT VS 3Y AVG
-2.28%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
CeriBell, Inc.
Market Cap
$928.46M
Net Profit Margin
-64.73%
TTM Avg
-64.32%
3Y Avg
-63.29%
5Y Avg
N/A
Market Cap
$928.65M
Net Profit Margin
-4994.86%
TTM Avg
-4994.86%
3Y Avg
-4994.86%
5Y Avg
-4994.86%
Market Cap
$925.11M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$923.25M
Net Profit Margin
-384.30%
TTM Avg
-367.92%
3Y Avg
-183.96%
5Y Avg
-122.64%
Market Cap
$914.14M
Net Profit Margin
6.60%
TTM Avg
6.45%
3Y Avg
5.72%
5Y Avg
5.15%
Market Cap
$894.27M
Net Profit Margin
9.36%
TTM Avg
-0.92%
3Y Avg
-15.83%
5Y Avg
-8.95%
Market Cap
$885.96M
Net Profit Margin
84.23%
TTM Avg
-685.46%
3Y Avg
-487.63%
5Y Avg
-594.40%
Market Cap
$976.67M
Net Profit Margin
19.87%
TTM Avg
-292.21%
3Y Avg
-499.51%
5Y Avg
-430.28%
Market Cap
$977.57M
Net Profit Margin
-727.04%
TTM Avg
-1969.28%
3Y Avg
-984.64%
5Y Avg
-984.64%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $928.46M | -64.73% | -64.32% | -63.29% | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $928.65M | -4994.86% | -4994.86% | -4994.86% | -4994.86% |
| MoonLake Immunotherapeutics (MLTX)vs › | $925.11M | 0.00% | 0.00% | 0.00% | 0.00% |
| Kura Oncology, Inc. (KURA)vs › | $923.25M | -384.30% | -367.92% | -183.96% | -122.64% |
| HealthStream, Inc. (HSTM)vs › | $914.14M | 6.60% | 6.45% | 5.72% | 5.15% |
| Bioventus Inc. (BVS)vs › | $894.27M | 9.36% | -0.92% | -15.83% | -8.95% |
| Arbutus Biopharma Corp (ABUS)vs › | $885.96M | 84.23% | -685.46% | -487.63% | -594.40% |
| MeiraGTx Holdings plc (MGTX)vs › | $976.67M | 19.87% | -292.21% | -499.51% | -430.28% |
| Aktis Oncology, Inc. (AKTS)vs › | $977.57M | -727.04% | -1969.28% | -984.64% | -984.64% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $978.45M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-68.6%
Net Profit Margin
-64.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -68.58% |
| 2026-03-31 | -74.50% |
| 2025-12-31 | -54.58% |
| 2025-09-30 | -59.61% |
| 2025-06-30 | -64.36% |
| 2025-03-31 | -62.35% |
| 2024-12-31 | -67.85% |
| 2024-09-30 | -60.58% |
| 2024-06-30 | -58.76% |
| 2024-03-31 | -58.76% |
| 2023-12-31 | -63.01% |
| 2023-09-30 | -60.75% |
| 2023-06-30 | -69.01% |
| 2023-03-31 | -69.01% |
